Odette S. Reifsnider

Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial

Odette S. Reifsnider, Christoph Wanner, Egon Pfarr et al. · American Journal of Kidney Diseases · 2021 · 45 citations · Full text

Empa-reg Outcome Trial, United States, Renal Function +22

Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the <scp>EMPA</scp>‐<scp>REG OUTCOME</scp> trial

Odette S. Reifsnider, Irina Proskorovsky, Ying Zheng et al. · Diabetic Medicine · 2019 · 40 citations · Full text

Cost-Effectiveness of Empagliflozin in the UK in an EMPA-REG OUTCOME Subgroup with Type 2 Diabetes and Heart Failure

Odette S. Reifsnider, Jennifer Franke, Joseph H. Lee et al. · ESC Heart Failure · 2020 · 29 citations · Full text

Cost‐effectiveness analysis of empagliflozin versus sitagliptin as <scp>second‐line</scp> therapy for treatment in patients with type 2 diabetes in the United States

Odette S. Reifsnider, Pratik Pimple, Valerie Aponte Ribero et al. · Diabetes Obesity and Metabolism · 2020 · 24 citations · Full text

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

Odette S. Reifsnider, Pranav Gandhi, Lael Cragin et al. · BMJ Open Diabetes Research & Care · 2021 · 24 citations · Full text